Your browser doesn't support javascript.
loading
The prognostic significance of the 18F-fluorodeoxyglucose positron emission tomography/computed tomography in early-stage nonsmall cell lung cancer
J Cancer Res Ther ; 2020 Sep; 16(4): 816-821
Article | IMSEAR | ID: sea-213708
ABSTRACT
Context The prognostic criteria for early-stage nonsmall cell lung cancer (NSCLC) wait to be explored.

Aim:

In this study, our aim was to evaluate the prognostic significance of the positron emission tomography/computed tomography (PET/CT) maximum standardized uptake value (SUVmax) value of the primary tumor in patients with a diagnosis of early-stage NSCLC who received surgical treatment. Settings and

Design:

This was a multicenter retrospective design. Materials and

Methods:

Patients who had been diagnosed with early-stage NSCLC and who underwent surgery for the condition were included in this study. The preoperative fluorodeoxyglucose (18F-FDG) PET/CT results of the patients were retrospectively accessed from their medical files. The disease-free survival (DFS) rates of patients who had SUVmax values above and below the determined cutoff value were compared. Statistical Analysis Used SPSS version 22 and Kaplan–Meier method were used for statistical analysis.

Results:

A total of 92 patients were included in the study. The median age of the patients was 60 years (range 36–79). The determined cutoff SUVmax value of the primary tumor was 13.6. A comparison of the DFS rates of the patients with an SUVmax value above and below 13.6 revealed a significant difference in patients with Stage I (22.9 months vs. 50.3 months; P = 0.02) and Stage II (28 months vs. 40.4 months; P = 0.04), Stage I + II (43.5 months vs. 26.1 months; P = 0,02), and Stage IIIA (14.7 months vs. 13.6 months; P = 0.92) NSCLC.

Conclusions:

We found that in early-stage NSCLC patients, the SUVmax value of the primary mass in 18F FDG PET/CT was a prognostic indicator for the DFS rates

Full text: Available Index: IMSEAR (South-East Asia) Type of study: Controlled clinical trial / Prognostic study Journal: J Cancer Res Ther Journal subject: Neoplasms / Therapeutics Year: 2020 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: IMSEAR (South-East Asia) Type of study: Controlled clinical trial / Prognostic study Journal: J Cancer Res Ther Journal subject: Neoplasms / Therapeutics Year: 2020 Type: Article